890701 | 14:0 EPC (Cl Salt)
1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (chloride salt)
14:0 EPC (Cl Salt)
1,2-dimyristoyl-sn-glycero-3-ethylphosphocholine (chloride salt)
O-alkyl phosphatidylcholines constitute the first chemically stable triesters of biological lipid structures and the first cationic derivatives of phospholipids consisting entirely of biological metabolites linked with ester bonds. The lipid has low toxicity and is biodegradable.
CAS Registry Number is a Registered Trademark of the American Chemical Society
Evans KO, Compton DL, Kim S, Appell M. Charged phospholipid effects on AAPH oxidation assay as determined using liposomes. Chem Phys Lipids. 2019 Feb 21;220:49-56. doi: 10.1016/j.chemphyslip.2019.02.004. [Epub ahead of print]
PubMed ID: 30796887Koynova, R., Tenchov, B., Wang, L., MacDonald, R.C. (2009) Hydrophobic moiety of cationic lipids strongly modulates their transfection activity. Mol Pharm. 6:951-8. [PubMed]
PubMed ID: 19341312Tenchov, B.G., Wang, L., Koynova, R., MacDonald, R.C. (2008) Modulation of a membrane lipid lamellar-nonlamellar phase transition by cationic lipids: a measure for transfection efficiency. Biochim Biophys Acta. 1778:2405-12. [PubMed]
PubMed ID: 18722340Koynova, R., Tarahovsky, Y.S., Wang, L., MacDonald, R.C. (2007) Lipoplex formulation of superior efficacy exhibits high surface activity and fusogenicity, and readily releases DNA. Biochim Biophys Acta. 1768:375-86. [PubMed]
PubMed ID: 17156744Koynova, R., Wang, L., MacDonald, R.C. (2007) Synergy in lipofection by cationic lipid mixtures: superior activity at the gel-liquid crystalline phase transition. J Phys Chem B. 111:7786-95. [PubMed]
PubMed ID: 17571876Wang, L., MacDonald, R.C. (2007) Synergistic effect between components of mixtures of cationic amphipaths in transfection of primary endothelial cells. Mol Pharm. 4:615-23. [PubMed]
PubMed ID: 17408283Bicelles can be integrated into standard crystallization protocols, and in contrast to micelles, bicelles maintain the protein in a more native bilayer environment allowing proteins to be captured in a more biologically relevant orientation. Reference/Protocol
- Certificate of Analysis (Lot No. 890701C-10MG-A-020 and 6345CIA020)
- Certificate of Analysis (Lot No. 890701C-25MG-A-020 and 6345CJA020)
- Certificate of Analysis (Lot No. 890701P-10MG-A-020 and 6345PIA020)
- Certificate of Analysis (Lot No. 890701P-25MG-A-020 and 6345PJA020)
- Certificate of Analysis (Lot No. 890701P-25MG-B-020 and 6345PJB020)
- Certificate of Analysis (Lot No. 890701P-25MG-C-020 and 6345PJC020)
- Certificate of Analysis (Lot No. 890701P-25MG-D-020 and 6345PJD020)
- Certificate of Analysis (Lot No. 890701P-25MG-F-020 and 6345PJF020)
- Certificate of Analysis (Lot No. 890701P-25MG-E-020 and 6345PJE020)
- Certificate of Analysis (Lot No. 890701P-25MG-A-021 and 6345PJA021)
- Certificate of Analysis (Lot No. 890701P-10MG-A-021 and 6345PIA021)
- Certificate of Analysis (Lot No. 890701P-25MG-B-021 and 6345PJB021)
- Certificate of Analysis (Lot No. 890701P-25MG-A-025 and 6345PJA025)
- Certificate of Analysis (Lot No. 890701P-25MG-E-020 and 6345PJE020)
- Certificate of Analysis (Lot No. 890701P-25MG-B-023 and 6345PJB023)
- Certificate of Analysis (Lot No. 890701C-25MG-A-023 and 6345CJA023)
- Certificate of Analysis (Lot No. 890701P-10MG-A-023 and 6345PIA023)